Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) Q3 2025 earnings summary

Executive summary

• Achieved strong year-over-year growth in revenue and profit for the third quarter of 2025, driven by intensified market expansion and increased sales revenue.

• Net profit attributable to shareholders rose significantly, reflecting effective operational execution.

Financial highlights

• Income from operations for the quarter reached RMB 19.77 billion, up 9.74% year-over-year; year-to-date income was RMB 61.61 billion, up 4.31%.

• Net profit attributable to shareholders for the quarter was RMB 793.91 million, up 30.28% year-over-year; year-to-date net profit was RMB 3.31 billion, up 4.78%.

• Basic and diluted EPS for the quarter were RMB 0.488, up 30.28% year-over-year; year-to-date EPS was RMB 2.036, up 4.78%.

• Total assets as of September 30, 2025, were RMB 83.17 billion, up 1.82% from December 31, 2024.

• Total equity attributable to shareholders increased by 5.58% to RMB 37.91 billion.

Outlook and guidance

• Continued focus on market expansion and sales growth is expected to sustain profit momentum.